Email: m.fragiadaki@sheffield.ac.uk

Research profile and key clinical specialties

Chronic kidney disease is an area of unmet clinic need. My group uses cutting-edge technologies to understand key processes that lead to kidney failure in patients with Polycystic Kidney Disease (PKD) with a focus on inflammation, DNA damage and proliferation.

We aim to identify and use novel RNA therapeutics for patients suffering with genetic diseases, such as those with PKD.

Two key publications

• Fragiadaki, M et al – The controversial role of fibrosis in autosomal dominant polycystic kidney disease – PMCID: PMC7728143  DOI: 10.3390/ijms21238936 
• Patera F et al – Renal expression of JAK2 is high in polycystic kidney disease and its inhibition reduces cystogenesis PMID: 30872773 PMCID: PMC6418191  DOI: 10.1038/s41598-019-41106-3 

Possible PhD projects

• Pre-clinical testing of novel RNA therapeutics to combat PKD (nanoparticle based).
• Proteomics and single cell transcriptomics of the polycystic kidney – discovery of new therapeutic targets.
• Hypoxia and the polycystic kidney.

More information

Our work is currently funded by UKRI via a Future Leaders Fellowship & the Academy of Medical Sciences via a Springboard award. There are opportunities to apply for funding.

Keywords: Kidney, polycystic, PKD, DNA, proliferation, proteomics, hypoxia, polycystic, Maria, Fragiadaki, Sheffield

Related